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Background: The goals of neoadjuvant chemotherapy (NAC) are to reduce tumor volume and to offer a prognostic indicator in assessing treatment response. Contrast-enhanced Magnetic Resonance Imaging (CE-MRI) is an established method for evaluating response to NAC in patients with breast cancer.
Purpose: To validate the role of unenhanced MRI (ue-MRI) compared to CE-MRI for assessing response to NAC in women with breast cancer.
Material and methods: 71 patients with an ongoing NAC for breast cancer underwent MRI before, during and at the end of NAC. Ue-MRI was performed with T2 weighted sequence with iterative decomposition of water and fat and diffusion-weighted sequences. CE-MRI was performed using 3D T1-weighted sequences before and after administration of gadobenate dimeglumine. Two blinded observers rated ue-MRI and CE-MRI for the evaluation of tumor response. Statistical analysis was performed to compare lesion size and ADC values changes during therapy, as well as inter-observer agreement.
Results: There were not statistically significant differences between ue-MRI and CE-MRI sequences for evaluation of lesion size at baseline and after every cycle of treatment (p>0.05). 
The mean tumor ADC values at baseline and across the cycles of NAC were significantly different for responder group.
Conclusion: Ue-MRI can achieve similar results to CE-MRI for the assessment of tumor response to NAC. ADC values can differentiate responders from non-responders. 
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Introduction
Patients with locally advanced primary breast cancer are at increased risk of metastatic disease. These patients often receive neoadjuvant chemotherapy (NAC), even if the tumor is primarily operable (1). The principal goals of NAC are to reduce tumor volume and to offer a prognostic indicator in assessing treatment response (2). The possibility of reducing in size large tumors is frequently important in facilitating breast conservation surgery which might otherwise not be achievable, while early assessment of treatment response impacts positively on overall survival and outcome (3, 4). Given the potential toxicity of chemotherapeutic drugs, early assessment of tumor response is particularly beneficial for patient management decisions, especially in cases of progressive disease. A further benefit of NAC is in providing an early opportunity to treat micrometastatic disease (5). 
Currently, contrast-enhanced MR imaging (CE-MRI) is an established method for evaluating response to NAC in patients with breast cancer. Several studies have demonstrated high correlation between tumor size measured at CE-MRI using RECIST 1.1 criteria (Response Evaluation Criteria in Solid Tumors) (6) and histopathological specimens obtained after NAC (7-9). The European Society of Breast Imaging (EUSOBI) recommends CE-MRI before, during, and after NAC (10). Apart from providing morphologic information, the value of dynamic CE-MRI is that it permits evaluation of the functional properties of tumors, allowing detection of reduced enhancement washout independently from their reduction in size (11). Unfortunately, contrast agent use increases both examination time and costs; moreover, they cannot be administered in patients with gadolinium intolerance/allergies. 
In recent years, the potential role of unenhanced MRI (ue-MRI) based only on diffusion-weighted imaging (DWI) and T2 weighted sequences, has been described for mass lesion detection (12, 13). Findings from these studies suggest that differentiation of benign from malignant breast lesions may be achievable with high sensitivity and specificity through a combination of DWI with T2-weighted sequences. The potential advantages of this approach, apart from cost and time savings, are that breast MRI might still be feasible in patients not suitable for contrast agent administration and that patient comfort is increased as intravenous line positioning is no longer required. 
Recently, T2-IDEAL (Iterative Decomposition of water and fat with Echo Asymmetry, GE Healthcare) has been proposed for breast imaging (14). This approach is a chemical shift-based fat-water separation method that can be applied to a variety of MR pulse sequences and which allows the acquisition of 4 complete imaging datasets (T2 weighted in-phase images, T2 weighted out-of-phase images, T2 water only images and T2 fat only images).
Ue-MRI using a combination of DWI and T2-IDEAL sequences may be a promising alternative to CE-MRI in breast imaging for the assessment of lesion size and tumor conspicuity. With this in mind we compared ue-MRI using combined DWI and T2-IDEAL with CE-MRI for the assessment of response to NAC. 

Material and Methods
Consecutive female patients with locally advanced breast cancer with indication to NAC were prospectively enrolled between January 2010 and September 2014. Women with contraindications for CE-MRI were excluded from the study. The study was approved by the ethical and protocol review committees of our institution and all patients provided written informed consent.

Patient treatment
Eighty-three patients with advanced breast cancer, proven by core biopsy, underwent breast CE-MRI before and at the end of each cycle of NAC; type and cycles number of NAC were scheduled on the basis of the molecular profile and tumor histology.
All patients underwent surgery within 20 days after the last MRI examination. Histopathological analysis of the surgical specimens was performed in all cases. 
MRI response to NAC was assessed using RECIST 1.1 criteria (6). Complete pathological response was defined as the absence of invasive cancer within the specimen. Incomplete pathological response was defined as the presence of residual invasive carcinoma of any size. 

Imaging procedures
Breast MRI was performed on a 3 Tesla magnet (Discovery MR750, GE Healthcare, Milwaukee, Wisconsin, USA) using an 8 channel bilateral breast surface coil with the patient in the prone position.
The MRI protocol included FSE T2 IDEAL sequences, DWI sequences and Vibrant 3D T1-weighted (GE Healthcare) sequences acquired before and after the intravenous administration of gadolinium contrast agent (gadobenate dimeglumine [MultiHance]; Bracco Imaging SpA, Milan, Italy). The T2-weighted IDEAL sequence was acquired with: TR/TE: 9,128/120 ms; flip angle: 30°; matrix: 242×256 pixels; field-of-view (FOV): 340 mm; slice thickness: 3 mm; acquisition time: 200 sec. The multiecho-single-shot EPI-DWI sequence was acquired with TR/TE: 6,840–6,236/51 ms; ETL: 37; matrix: 128×87; FOV: 36×36 cm; section thickness: 5 mm; intersection gap: 1.5 mm; NEX 2; parallel imaging reduction factor: 2; b values: 0, 800, 1000 mm2/sec. The Vibrant fast 3D FS T1-weighted sequence was acquired with TR/TE: 7.7/4.2 ms; TI: 20 flip angle: 10°; matrix: 256×512; FOV: 350×490 mm; slice thickness: 1.2 mm; acquisition time: 120 sec before and 2, 4, 6 and 8 min after injection of gadobenate dimeglumine at a dose of 0.1 mmol/kg bodyweight. Gadobenate dimeglumine was injected at a flow rate of 2 mL/s through an antecubital venous access by means of a power injector (Spectris, Medrad, Warrendale, Palo Alto, CA, USA) and was followed by 20 mL of saline flush administered at the same rate.

Image analysis
Image analysis was performed on an offline dedicated workstation separately by two independent readers (with 5 and 9 years of experience in breast MRI) who were fully blinded to all patient demographic and clinical information. In order to prevent a recall bias, ue-MR and CE-MR images of patients were presented randomly to the 2 independent readers. Initial evaluation was performed of combined ue-MRI images for tumor response which was measured in terms of tumor size, tumor appearance and Apparent Diffusion Coefficient (ADC) values. After an intervening period of at least two weeks all CE-MRI images were evaluated using the same assessment criteria used for evaluation of the ue-MRI images. 

Lesion size 
Lesion size was determined separately on the T2 IDEAL sequence, on b-1000 DWI images and on VIBRANT T1-weighted CE-MRI images (second post-contrast dynamic acquisition). Tumor size on T2 IDEAL sequence was expressed as the mean of the lesion sizes determined on the evaluation of the four imaging datasets. If multicentric or multifocal disease was present, the lesion with greatest dimensions  was considered for size measurements. 
Assessment of MR images was based on the Breast Imaging Reporting and Data System (BI-RADS) MRI lexicon (15). Lesions were considered as demonstrating mass or non-mass enhancement.

Apparent diffusion coefficient
ADC maps were generated from the DWI datasets of each study using a semiautomatic software tool (Functool; GE Healthcare) on an offline workstation (ADW 4.4; GE Healthcare) with a gray-scale indicating low ADC values in black. The ADC value was measured by placing a circular regions of interest (ROI) with a diameter of 6 mm within the darkest portion of individual lesions by two readers in consensus. 

Evaluation of tumor response
The response to NAC was evaluated separately on the ue-MRI and CE-MRI sequences for each patient. Tumor response to NAC was classified using RECIST 1.1 criteria as: 1) complete response (absence of residual mass); 2) partial response (≥30% reduction in tumor size); 3) stable disease (<30% reduction or <20% increase in tumor size); 4) progressive disease (≥20% increase in tumor size). 
Based on these criteria, patients were classified as responders, partial responders or non-responders (the latter including stable disease and progressive disease) on T2 IDEAL+DWI images and on dynamic CE-MRI images. Imaging results from the last MRI were then compared with findings of surgery obtained histological specimens. Pathological evaluation of response to NAC was conducted using Residual Cancer Burden Score of MD Anderson Cancer Center.
In the last MR examination, for partial responders group, the shrinkage patterns of residual disease was also classified as concentric (without surrounding lesion) or scattered (shrinkage with residual multinodular lesions).

Statistical analysis
Data were collected using an electronic datasheet. The statistical analysis was performed using a dedicated statistical software package (SPSS Statistics 19 for Macintosh; IBM Company, Armonk, New York, U.S.A.) and Matlab 9 (the MathWorks, Natick, MA, U.S.A.) as deemed appropriate. The Bland-Altman analysis was done using an additional tool by Ran Klein, the Bland-Altman and Correlation Plot v1.3 (https://uk.mathworks.com/matlabcentral/fileexchange/45049-bland-altman-and-correlation-plot?requestedDomain=www.mathworks.com).
All continuous values were expressed as mean ± SD. 95% confidence intervals (CI) and were identified with statistical significance set at p<0.05 for all tests performed. The Kolmogorv-Smirnov test was used to test data distribution. Bonferroni was used to correct multiple pairwise comparisons.
Lesion size on T2-IDEAL, DWI, combined T2-IDEAL + DWI sequences and pathology were compared across cycles using Spearman’s correlation coefficient. Moreover, Bland-Altman plots were used to test differences between baseline and after the 2nd and the 6th cycle of therapy. One-way ANOVA was used to test differences in percentage changes between the baseline scan and the follow-up scans. Inter-observer agreement concerning lesion size measurements was analyzed using Cohen κ coefficients in which κ values of 0.21–0.40 indicates poor agreement, 0.41– 0.60 moderate agreement, 0.61–0.80 good agreement and 0.81–1.00 excellent agreement. 
A comparison of quantitative tumor ADC values at baseline and after NAC was likewise performed using a paired sample t-test. These results were stratified by dividing patients into two groups based on histopathological findings: group A (responders) and group B (partial responders, stable disease and non-responders). 

Results 
Of 83 enrolled patients, 12 underwent surgery before completing all 6 cycles of NAC. These patients were then excluded from the analysis in order to homogenize as much as possible the patient population. Seventy-one consecutive female patients (mean age: 44 ± 10 [range: 34-74]) that completed all 6 cycles of NAC were then considered as final study population. Nine (12.9%) of these patients were post-menopausal, 18 (25.8%) were peri-menopausal and 43 (61.3%) were pre-menopausal. Histological analysis determined 64 (94%) lesions to be invasive ductal carcinoma (IDC) and 7 (10%) to be invasive lobular carcinoma (ILC). Multicentric and multifocal disease was observed in 15 and 11 patients respectively.

Image Analysis
Evaluation of tumor response
Based on histopathological assessment after surgery 36/71 (51%) patients were classified as complete responders to NAC (Figs. 1 and 2), while 32/71 (45%) patients were considered partial responders (Figs. 3 and 4) and 3/71 (4%) non-responders. In partial responders group, the shrinkage pattern of the lesion was classified as “scattered” in 8/32 patients (25%) and “concentric” in 24/32 patients (75%).

Lesion size and characteristics
Overall, 56/71 (79%) lesions were classified as mass lesions. The remaining 15/71 (21%) lesions demonstrated non-mass enhancement. 
The mean size of lesions on different sequences at baseline and during NAC is shown in Table 1. The Kolmogorv-Smirnov test showed that data distributions were not Gaussian. Fig. 5 illustrates the results of the one-way ANOVA for T2-IDEAL, CE-MRI, DWI and T2-IDEAL+DWI; there were not statistically significant differences between those modalities across all the time points (p>0.05). The correlation between the MRI derived parameters at baseline was good (r2 = 0.65) after the 2nd cycle and moderate (r2 =0.46) after the 6th cycle. The Bland-Altman analysis showed a good agreement between the measures (Fig. 6).

ADC quantitative analysis
Quantitative analysis of DWI ADC values was performed at time zero and after 2, 4 and 6 cycles of NAC. The mean ADC values at time zero and across the cycles of NAC for the whole study group were significantly different (Table 2).
Stratification of ADC findings into group A (responders) and group B (non-responders plus partial responders) revealed a significant difference before and after NAC for group A (p=0.003), but not for group B (p=0.08; Table 2). 

Discussion
Breast MRI is the most accurate diagnostic method for the assessment of breast disease (17, 18, 19). Breast MRI is considered the most reliable method for monitoring tumor response to chemotherapy and predicting the extent of residual disease after NAC (20-22). One of the main issues of the technique at this time is related to the use of contrast agent. Even if gadolinium-based contrast agents are widely used and have been considered to have a wide safety margin in patients with normal renal function, a deposition of gadolinium in different tissues have been described, such as kidneys (with consequent potential development of nephrogenic systemic fibrosis), bone matrix, skin and brain (23, 24). This deposition could increase with repeated gadolinium contrast administrations, despite an intact blood-brain barrier and normal renal function (25). Moreover, there are other advantages in avoiding repeated contrast agent administrations. Indeed, a reduction in the use of contrast agents will determine a significant shortening in both acquisition time and reading time, with consequential decrease in costs. Although it may not be as relevant in this setting as it may be for example for screening purposes, this is still an advantage of this approach on a macro-scale. Lastly, patient comfort may be increased as IV line positioning is no longer required and, therefore, patient compliance could increase. 
In recent years, the potential role of ue-MRI based only on DWI and T2w sequences has been described for mass lesion detection (12, 13). Available data suggest that a combination of DWI and T2-weighted TSE may offer potential for the differentiation of benign from malignant breast lesions with high sensitivity and specificity. 
It is well known that CE-MRI is essential for the evaluation of size and the vascular patterns of breast lesions. Nevertheless, our findings suggest that the morphological information from T2w images together with the cellular information available on DWI images is able to provide similarly useful information for the accurate evaluation of tumor response. 
Analysis of the four different images obtained with the T2-IDEAL sequence gives important data concerning lesion size measurements and the detection of associated features (for example the presence of tissue edema). The main limitation of T2w imaging is often seen in the evaluation of non-mass enhancement (NME), frequently represented by DCIS. However Rahbar et al (26) showed that T2-weighted images combined with DWI can play an important role in detecting DCIS. In their study, Rahbar et al. retrospectively reviewed 74 pure DCIS and observed that 96% of these lesions demonstrated greater qualitative and quantitative DWI intensity and lower ADC values than that of normal breast tissue. The study reported a 95% detection rate of DCIS supporting DWI as a potential method for early breast cancer detection without contrast material injection. In our study, 4 cases of invasive carcinomas presenting as NME were underestimated comparing to CE-MRI when reading the T2-IDEAL alone; in particular, T2-IDEAL was able to detect the tumor at baseline, but it failed to identify the residual pathologic tissue at MRI before surgery. This limit was overcome by the association of T2-IDEAL and DWI that correctly depicted the residual tumor in all cases. When evaluating T2-IDEAL images together with DWI for lesion size assessment we obtained better results at all time-points.
We also demonstrated good inter-observer reproducibility of size measurements suggesting that this technique may be appropriate for clinical routine for the follow-up of patients undergoing NAC. 
In the presented study we reported a change of ADC values in patients undergoing NAC, with a significant difference between ADC values before and after NAC (Tab. 2). When stratifying our patients into two groups based on response to NAC treatment (responders: A, non-responders: B), the difference in ADC values between the two groups was even more relevant. These data correlate well with literature reports (27-29) and confirm that ADC values are a useful indicator for the evaluation of response to NAC.
Despite these promising results, our study has some limitations. First, ADC measurements require manual placement of the region of interest which makes the method highly operator dependant (30). Moreover lesion heterogeneity and the larger spatial distribution of non-mass enhancement could decrease the reproducibility of ADC values (31). 
Second, our study population was relatively small which prevented us from analyzing potential differences related to different chemotherapeutic drugs and different tumour’s histotype. For example, despite the large number of complete response to therapy, we had only 2/7 cases of complete response in invasive lobular cancers. It is true that in general invasive lobular breast cancers are less likely to experience pCR after chemotherapy and that physicians currently give much importance to hormone receptor assay more than histological type of tumour. Anyway, given the very small number of lobular cancers in the presented study, we cannot state if response to therapy of these cases depended on the histotype more than the hormone receptor assay.
Nevertheless, the promising results obtained in this study deserve validation in a larger prospective study.
In conclusion, the combination of T2-IDEAL for lesion morphology and size assessment and DWI for assessment of tumor cellularity and cell membrane integrity is potentially a useful approach for the follow-up of tumor response during NAC, while CE-MRI remains indispensible for depiction and first staging of the disease. The combination of T2-IDEAL and DWI sequences allows assessment of the response to chemotherapy with MRI. The similar results obtained for ue-MRI and CE-MRI suggest that the contrast agent free approach may be a good option in patients with locally advanced breast cancer undergoing NAC, saving time and costs and preventing potential tissue damage due to repeated injections of contrast agents. 
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Table 1: The mean size of lesions (mm) on different sequences at baseline and during neoadjuvant chemotherapy is shown.


















Table 2: The mean ADC values before and after neoadjuvant chemotherapy are shown for the whole study group as well as for responders and non-responders group. 
	ADC values (mm2/s)
	Whole study group	Responders	Non responders
Before NAC	1.20.2	1.30.3	1.20.2
After 2 cycles of NAC	1.20.6	1.70.2	1.10.6
After 4 cycles of NAC	1.00.7	2.00.2	1.00.7







Fig. 1: 48-year-old woman with invasive ductal carcinoma of the left breast. Baseline breast MRI (before NAC). DWI image (b1000) (1a) shows a 2.8 cm area of hyperintensity in the retroareolar region. In the homolateral axilla another area of hyperintensity measuring 1.3 cm is detected. T2w IDEAL image with fat saturation (1 b) reveal a parenchymal distortion in the retroareolar region and an abnormal lymph node in the homolateral axilla. T1w CE-MRI subtracted image (1c) shows a mass enhancement lesion of 2.9 cm in the retroareolar region. 

Fig. 2: Same patient as in Figure 1 after 6 cycles of neoadjuvant chemotherapy. DWI image (b1000) (2a) shows a reduction of the hyperintense retroareolar area and the lymph node. T2w IDEAL sequence with fat saturation (2 b) showa that the parenchymal distortion is no longer visible and the size of the lymphoadenopathy is reduced.  At T1w CE-MRI subtracted image (2c) no enhancement is visible at the end of NAC. After surgery, pathology confirmed the complete response.

Fig. 3: 67-year-old woman with biopsy-proven invasive ductal carcinoma of the right breast. Baseline MRI. DWI and water-only T2w IDEAL images (3 a, b) show a 50 mm neoplastic mass located between upper quadrants. Water-only images show diffuse edema surrounding the lesion and at the level of the skin and the pectoral muscle. T1w CE-MRI subtracted image (3c) confirm a 53 mm enhancing mass.

Fig. 4: Same patient after 6 cycles of neoadjuvant chemotherapy. DWI and T2w IDEAL images (4 a, b) show the persistence of a 33 mm tumor; water-only images show a reduction of the edema surrounding the lesion and within the pectoral muscle, with persistent edema at the level of the skin. T1w CE-MRI subtracted image (4 c) confirm the 53 mm enhancing mass. Histopathology confirmed a 40% reduction of the lesion (partial responder). 

Fig. 5: Analysis of differences expressed in percentage across the time points.

Fig. 6: Correlation between MRI parameters at baseline after the 2nd cycle (a) and the 6th cycle (c); b and d represents Bland-Altman plots of the same timepoints.
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